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Abstract
Humans possess three major isoforms of the apolipoprotein E (ApoE) gene encoded by three 
alleles: ApoE ε2 (ApoE2), ApoE ε3 (ApoE3), and ApoE ε4 (ApoE4). It is established that the 
three ApoE isoforms confer differential susceptibility to Alzheimer’s disease (AD); however, an 
in-depth molecular understanding of the underlying mechanisms is currently unavailable. In this 
study, we examined the cortical proteome differences among the three ApoE isoforms using 6-
month-old female, human ApoE2, ApoE3, and ApoE4 gene-targeted replacement mice and two-
dimensional proteomic analyses. The results reveal that the three ApoE brains differ primarily in 
two areas: cellular bioenergetics and synaptic transmission. Of particular significance, we show for 
the first time that the three ApoE brains differentially express a key component of the catalytic 
domain of the V-type H+-ATPase (Atp6v), a proton pump that mediates the concentration of 
neurotransmitters into synaptic vesicles and thus is crucial in synaptic transmission. Specifically, 
our data demonstrate that ApoE2 brain exhibits significantly higher levels of the B subunit of 
Atp6v (Atp6v1B2) when compared to both ApoE3 and ApoE4 brains, with ApoE4 brain 
exhibiting the lowest expression. Our additional analyses show that Atp6v1B2 is significantly 
impacted by aging and AD pathology and the data suggest that Atp6v1B2 deficiency could play a 
role in the progressive loss of synaptic integrity during early development of AD. Collectively, our 
findings indicate that human ApoE isoforms differentially modulate regulatory mechanisms of 
bioenergetic and synaptic function in female brain. A more efficient and robust status in both areas 
could serve as a potential mechanism contributing to the neuroprotective and cognition-favoring 
properties associated with the ApoE2 genotype.
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Introduction
Alzheimer’s disease (AD) currently affects 35 million people worldwide, including 5.4 
million Americans [1]. At present, the underlying cause of AD is unknown and an effective 
treatment is yet to be established. The past 15 years of research have yielded over 200 
clinical trials aimed at the treatment of AD; all of which have failed to succeed [2, 3]. The 
unanticipated challenges associated with the development of a successful treatment 
combined with the estimated rapid increases in AD prevalence stress the importance of 
identifying the underlying AD risk-mechanisms that would allow prevention, risk reduction, 
and early intervention in the preclinical stage of AD [4].
Apolipoprotein E (ApoE) is peripherally synthesized and secreted by the liver where it 
regulates the transport of cholesterol, lipoproteins, and fat-soluble vitamins [5, 6]. In the 
brain, ApoE is synthesized and secreted by astrocytes and functions to transport cholesterol 
into neurons via interaction with ApoE receptors [7]. The human ApoE gene exists as three 
major isoforms encoded by three polymorphic alleles: ε2, ε3, and ε4. The three translated 
ApoE proteins differ sequentially by two amino acid substitutions at residues 112 and 158: 
ApoE2 (Cys112, Cys158), ApoE3 (Cys112, Arg158), and ApoE4 (Arg112, Arg158) [8, 9]. 
These amino acid differences affect the 3D structure of ApoE and are suggested to alter the 
ability of ApoE to bind lipids [10], LDL receptor [11], and Aβ [12, 13]. Apart from 
structural differences, the population distribution and associated AD risk of ApoE alleles 
also differ significantly. ApoE3, the most common ApoE isoform, is present in 75% of the 
population and is considered to be risk-neutral [14]. ApoE2 is relatively rare, with only 5% 
incidence, and is considered to be a neuroprotective variant [15]. In contrast, ApoE4, 
occurring in 20% of the population, is present in nearly 50% of AD patients [16].
As the greatest genetic risk factor for AD [16], ApoE4 is clinically associated with an 
increased rate and severity of cognitive decline [17–19], a younger age of onset [20], and 
altered response to AD treatments [6]. On the molecular level, ApoE4 has been shown to 
reduce brain glucose utilization [21], increase neuronal inflammation [22], and is associated 
with increased Aβ dyshomeostasis [23, 24]. Moreover, multiple studies have demonstrated 
that ApoE4-associated AD risk is significantly more pronounced in the female population 
[25–27]. For example, a recent longitudinal study conducted in a cohort of 8,084 elderly 
individuals (healthy controls: n=5,496; MCI cases: n=2,588) demonstrated that the risk of 
clinical conversion from healthy aging to MCI or from MCI to AD conferred by the ApoE4 
allele is significantly greater in women than in men [28]; a finding that corresponds with 
several earlier reports [29, 30]. Contrarily, possession of the ApoE2 allele has been 
associated with significantly decreased susceptibility for AD and improved cognitive 
function in the aging brain particularly in the male population [31]. A 3-year follow-up 
study conducted in 917 non-demented elderly subjects revealed that subjects possessing the 
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ε2/ε2 or ε2/ε3 genotype maintained consistent verbal learning performance while the 
learning ability of subjects with alternative ApoE genotypes deteriorated [32]. An additional 
8-year cohort study involving 669 elderly individuals determined that subjects who 
possessed one or more copies of the ε2 allele exhibited improved episodic memory, while 
episodic memory declined sharply in subjects possessing one ε4 allele [33].
While there exists an abundance of research demonstrating the neurodegenerative impact of 
the ApoE4 status, far less is known about the mechanisms by which ApoE2 exhibits 
neuroprotection. To address this research gap, our laboratory has initiated a series of novel 
studies designed to identify the molecular differences that separate ApoE2 brain from 
ApoE3 and ApoE4 brains, which could contribute to the neuroprotective properties of 
ApoE2. We have recently shown that the three human ApoE isoforms differentially 
modulate signaling pathways involved in glucose uptake and metabolism; compared to 
ApoE3 and ApoE4 brains, the ApoE2 brain exhibits the most bioenergetically robust profile, 
providing a possible mechanism whereby ApoE2 delegates neuroprotection [34]. In the 
current study, we continued our examination of the three ApoE isoforms in female, human 
ApoE2, ApoE3, and ApoE4 gene-targeted replacement mice. Using two-dimensional (2D) 
proteomics coupled with liquid chromatography mass spectrometry analyses (LC-MS/MS), 
we detected differential expression patterns of enzymes involved in bioenergetic and 
synaptic processes among the three ApoE brains. Of particular significance, we found for 
the first time that ApoE2 brain expresses a significantly higher level of a key component of 
the V-type H+-ATPase (V-ATPase; Atp6v), a proton pump that mediates neurotransmitter 
accumulation in synaptic vesicles and thus is essential in synaptic transmission. An 
extension of our proteomic analyses revealed that the expression of the B subunit of Atp6v 
(Atp6v1B2) is predominantly localized to the membrane of synaptic vesicles and is 
significantly impacted by aging and AD pathology. These data provide another possible 
mechanistic explanation for the neuroprotective properties associated with the ApoE2 
genotype and present a possible molecular entity that could be targeted to sustain synaptic 




The use of animals was approved by the Institutional Animal Care and Use Committee at the 
University of Kansas and followed NIH guidelines for the care and use of laboratory 
animals. This study was carried out in human ApoE2, ApoE3, and ApoE4 gene-targeted 
replacement (hApoE2-TR, hApoE3-TR, and hApoE4-TR) mouse models. These mouse 
lines were created by gene targeting and carry one of the three human ApoE alleles in place 
of the endogenous murine ApoE gene while retaining the endogenous regulatory sequences 
required for modulating hApoE expression [35]. These mice share a C57BL/6J genetic 
background and express the hApoE protein at physiological levels; thus, they provide a 
complete in vivo system that allows direct measurement and comparison of hApoE isoform-
specific effects. The following experiments were conducted on cortical tissues collected 
from 6-month-old hApoE2-TR, hApoE3-TR, and hApoE4-TR female mice (n=3 for 
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proteomic analyses; n=5 for immunoblot analyses). For aging and pathology studies, cortical 
tissues were collected from female 129/C57BL/6 and female triple transgenic AD (3xTg-
AD) mice at ages of 6, 9, 12 and 15 months (n=4–5 for each age group). The 3xTg-AD 
mouse model harbors three human AD-relevant generic alternations: APPswe, PS1M146V and 
tauP301L [36]. On the day of sacrifice, brain tissues were immediately dissected on ice; 
brains were separated into the left and right hemispheres and hippocampal and non-cortical 
tissues were removed. The remaining left and right cortices were cut into two pieces 
yielding a total of 4 cortical samples (left – upper, left – lower, right – upper, and right – 
lower) which were immediately flash frozen in dry ice. In the studies presented here, one 
piece of isolated cortical tissue (left – upper) from each animal was processed for protein 
extraction as indicated.
Protein extraction, isoelectric focusing, and 2D-PAGE
Cortical tissues from 6-month-old female hApoE2-TR, hApoE3-TR, and hApoE4-TR mice 
were homogenized using the Bullet Blender 24 Homogenizer (Next Advance, Averill Park, 
NY) in sample lysis buffer (7 M urea, 2 M thiourea, 4% CHAPS, 40 mM Tris pH 8–9, 100 
mM dithiothreitol (DTT), 0.2% BioLyte 3–10 ampholyte) supplemented with protease and 
phosphatase inhibitors with 100 μL 0.5 mm glass beads at speed 8 for 3 min at 4°C followed 
by centrifugation at 12,000 rpm for 8 min at 4°C. Homogenates were transferred to a new 
microcentrifuge tube and protein concentration was determined via BCA assay (Thermo 
Scientific, Grand Island, NY). 150 μg of homogenized cortical protein sample was 
precipitated using cold 100% trichloroacetic acid (TCA) to obtain a concentration of 15% 
(v/v) TCA in solution and incubated on ice for 15 minutes. Samples were centrifuged at 
14,000 rpm for 10 min at 4 °C. The resulting pellets were washed four times by re-
suspension in a 1:1 (v/v) cold ethanol: ethyl acetate solution. Following the final wash, 
pellets were completely dried at RT and re-hydrated in 200 μL rehydration buffer (8 M urea, 
2 M thiourea, 20 mM DTT, 2.0% (w/v) CHAPS, 0.2% Biolytes, trace amount Bromophenol 
Blue) for 2 hr at RT followed by vortexing for 15 seconds at 100% power. Total samples 
were added to each lane of the IEF tray and an 11 cm pH 3–10 ReadyStrip IPG Strip (Bio-
Rad, Hercules, CA) was placed on top. Samples were run for 45 min, paused and overlaid 
with 2 mL of mineral oil to prevent evaporation during the IEF process. Strips were actively 
rehydrated at 20 °C for 18 h at 50 V, focused at a constant temperature of 20 °C beginning at 
300 V linear for 2 h, 500 V linear for 2 h, 1000 V linear for 2 h, 8000 V linear for 8 h, and 
finishing at 8000 V rapid for 10 h. Following completion of IEF, IPG strips were stored at 
−80 °C until required for second dimension analysis. Prior to gel electrophoresis, IEF strips 
were allowed to acclimate to RT for approximately 30 min followed by incubation for 10 
min in the dark in 4 mL equilibration buffer A (1.5 M Tris-HCl, pH 8.8, 6 M urea, 1% (w/v) 
SDS, 30% v/v glycerol, 0.5% DTT) followed by 10 min incubation in equilibration buffer B 
(1.5 M Tris-HCl, pH 8.8, 6 M urea, 1% (w/v) SDS, 30% v/v glycerol, 4.5% Iodoacetamide 
(IAA)). Equilibrated IPG strips were immersed in TGS running buffer to remove any 
residual equilibration buffer and then placed onto 8–16% linear gradient pre-cast Criterion 
Tris-HCl polyacrylamide gels (Bio-Rad). Fresh agarose was overlaid and allowed to set on 
the strips to ensure complete adhesion to the 2D gel. Gels were resolved for 10 min at 80 V 
followed by a constant voltage of 200V for 50 min.
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SYPRO Ruby staining and gel image analysis
Following electrophoresis, gels were placed in fixing solution (7% acetic acid v/v, 10% 
methanol v/v in water) and incubated for 60 min at RT with continuous rocking. Gels were 
then incubated in 50 mL SYPRO Ruby fluorescent gel stain (Bio-Rad) overnight at RT with 
constant rocking. Following overnight incubation, SYPRO Ruby stain was removed and the 
gels were washed and stored in 50 mL ddH20. SYPRO Ruby-stained gels were scanned 
using a Typhoon Trio Scanner (Amersham Biosciences, Pittsburg, PA) set at normal 
sensitivity with excitation and emission wavelengths of 470 and 618 nm and saved as TIFF 
files. PDQuest 2D analysis software (Bio-Rad) was then utilized to adjust the size and 
orientation of the images via cropping and rotating tools followed by spot alignment across 
gels from different genotypes. For this set of experiments, which were carried out in 
triplicate, one reference gel was generated and automatic gel comparison to the reference gel 
was performed. Protein spots were standardized to the total density detected in each 
individual gel image. From this analysis, a total of 270 protein spots (101 spots in ApoE2 vs 
ApoE3 and 169 spots in ApoE2 vs ApoE4) were identified. Using the Student’s t-test, 37 
spots (18 spots in ApoE2 vs ApoE3 and 19 spots in ApoE2 vs ApoE4) were determined to 
be statistically significant (p<0.05).
Spot excision, trypsin digestion, LC-MS/MS and database search
Of the 37 spots identified, 20 spots were selected for protein identification using LC-
MS/MS; and these spots remained significant from the additional one-way ANOVA with 
Student-Newman-Keuls post-hoc test. These spots were excised from 2D gels using a UV 
transilluminator and sterilized micropipette tips and transferred to sterile microcentrifuge 
tubes in deionized water. Excised spots were then de-stained by incubation with 200 mM 
NH4HCO3/50% (v/v) acetonitrile at 37°C. Following incubation, solutions were removed 
from the tubes and gel plugs were allowed to dry under constant airflow in a sterile hood. 
Gel pieces were then reduced by incubation with dithiothreitol (DTT) at 60°C for 30 min 
and alkylated by incubation with IAA at RT for 30 min. Trypsin (Promega, Madison, WI) 
was added to the gel plugs in 200 mM NH4HCO3/10% (v/v) acetonitrile and incubated 
overnight at 37°C. Digested protein samples were analyzed by LC-MS/MS using a 
NanoAcquity chromatographic system coupled to an LTQ-FT mass spectrometer. Peptides 
were separated on a reverse-phase C18 column, 15 cm, 300 μm i.d. (Thermo Acclaim 
PepMap300, 300 Å, 5 μm). A gradient was developed from 1 to 40% B in 50 min, ramped to 
95% B in 4 min, and held at 95% B for 5 min at a flow rate of 10 μL/min with solvents A 
(99.9% H2O, 0.1% formic acid) and B (99.9% acetonitrile, 0.1% formic acid). The 
electrospray ionization (ESI) source was operated with spray voltage of 2.8 kV, a tube lens 
offset of 200 V and a capillary temperature of 200 °C. All other source parameters were 
optimized for maximum sensitivity of the Met-Arg-Phe-Ala (MRFA) tetrapeptide MH+ ion 
at m/z 524.26. The instrument was calibrated using an automatic routine based on a standard 
calibration solution (caffeine, MRFA peptide, and a commercially available mixture of 
fluorinated phosphazines (Ultramark 1621). The data-dependent acquisition method for the 
mass spectrometer (version LTQ-FT 2.5.5) was set up using Xcalibur software (Thermo 
Scientific) and full MS survey scans were acquired at a resolution of 50 000 with an 
automatic gain control (ACG) target of 5 × 105. The five most abundant ions were 
fragmented in the linear ion trap by collision-induced dissociation with an AGC target of 2 × 
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103 or maximum ion time of 300 ms and the ion selection threshold was 500 counts. 
Analysis of MS/MS spectra for peptide and protein identification was performed by protein 
database searching using Mascot (Matrix Science, Boston, MA, and Version 2.3) and X! 
Tandem (The Global Proteome Machine Organization, Version 2010.12.01.1). The programs 
were set up to search the UniProt-Sprot database assuming trypsin as the digestion enzyme. 
The fragment ion mass tolerance was 0.20 Da and the parent ion tolerance was 20 ppm. 
Scaffold software was used to validate MS/MS based peptide and protein identifications. 
Peptide identifications were accepted if they could be established at greater than 95% 
probability as specified by the Peptide Prophet Algorithm.
Immunoblotting
Approximately 30 mg of cortical tissues collected from female hApoE mice, 129/C57BL/6 
mice and 3xTg-AD mice was processed for protein extraction using tissue protein extraction 
reagent (Thermo Scientific) supplemented with protease and phosphatase inhibitors. Protein 
concentrations were determined using a BCA protein assay kit (Pierce) according to the 
manufacturer’s instructions. 20 μg of each total protein sample was loaded and separated by 
10% SDS-PAGE. Resolved proteins were transferred to 0.2 μm pore-sized PVDF 
membranes and blocked with 2% blotting grade blocker (BioRad) in 1× TBST (100 mL 10× 
TBS (200 mM Tris, 1.5 mM NaCl, pH 7.6), 10 mL 10% Tween-20, 890 mL ddH2O) for 1 hr 
at RT with continuous rocking. Membranes were incubated with customized dilutions of the 
primary antibody anti-V-ATPase B2 (1:1000, Santa Cruz, Dallas, TX) at 4°C overnight, 
followed by incubation with the HRP-conjugated secondary antibody (1:5000, Pierce) for 1 
hr at RT. Bands were visualized using chemiluminescence with an ECL detection kit 
(BioRad) and scanned using the C-Digit Blot Scanner (LI-COR, Lincoln, NE). Following 
visualization, blots were stripped with restore PLUS Western blot stripping buffer (Thermo 
Scientific) and re-probed for β-tubulin (Pierce) immunoreactivity as the loading control. 
Relative intensities of the immunoreactive bands were quantified using the Image Studio 
Version 4.0 image digitizing software.
Immunocytochemistry
Primary hippocampal neurons were isolated from Day 18 embryonic rat pups as previously 
described [37] and grown for 15 days on poly-D-lysine treated coverslips (NeuVitro, 
Vancouver, WA) at a density of 1.5 × 105. Cells were fixed in 4% paraformaldehyde for 15 
minutes at room temperature (RT) and permeabilized in PBS + 0.5% Triton X-100 (PBST) 
for 5 minutes at RT. Cells were incubated for 2 hr at RT with customized dilutions of the 
primary antibodies: anti-V-ATPase B2 (1:100, Santa Cruz), anti-synaptophysin (1:500, 
Abcam, Cambridge, United Kingdom), and anti-tau (1:500; Thermo Scientific) in PBST 
supplemented with 0.5% bovine serum albumin (BSA, Sigma Aldrich). Triple-stained 
coverslips were then incubated for 1 hr at RT with customized dilutions of secondary 
antibodies including FITC-conjugated goat-anti-mouse (1:1000, Abcam), preadsorbed goat-
anti-rabbit-Cy3 (1:1000, Abcam) and preadsorbed donkey-anti-goat Alexa-Fluor 647 
(1:1000, Abcam) in PBST with 0.5% BSA. Coverslips were mounted on standard glass 
microscopy slides with vectashield mounting medium containing DAPI (Vector 
Laboratories) and sealed with clear nail polish. Confocal images were acquired using a 
customized Olympus IX81/spinning disk confocal inverted microscope (Olympus, 
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Yokogawa) equipped with an Olympus 60× 1.45 NA oil immersion objective (Olympus). 
Images were collected and analyzed using the Slidebook Version 6.0 imaging software 
(Intelligent Imaging Innovations, Denver, CO) with 20–25 image stacks with a 0.10 μm step 
size through the cells.
Campbell-Switzer silver staining of Aβ plaques
Mouse hemispheres were sectioned using MultiBrain processing technology at 
NeuroScience Associates (NSA; Knoxville, TN). Briefly, hemispheres were treated with 
20% glycerol and 2% DMSO to prevent freeze-artifacts and subsequently embedded 
together in a gelatin matrix. After curing, the block of embedded hemispheres was rapidly 
frozen by immersion in isopentane chilled to −70°C with crushed dry ice and mounted on a 
freezing stage of an AO 860 sliding microtome. The block was sectioned at 35 μm in the 
coronal plane through the hippocampus region of the mouse hemispheres (Bregma −0.5 to 
−4.5 mm). Cut sections were collected sequentially into 12 containers that were filled with 
antigen preserve solution (50% PBS, 50% ethylene glycol and 1% polyvinyl pyrrolidone, pH 
7.0). Campbell-Switzer silver staining that labels Aβ plaques was performed on a serial set 
of one-of-every-4th (140 μm interval) sections of mouse hemispheres. Briefly, the sections 
were placed in freshly prepared 2% ammonium hydroxide for 5 minutes. The sections were 
next placed in a silver-pyridine-carbonate solution for 40 minutes, 1% citric acid for 3 
minutes, and 0.5% acetic acid until ready for development. The sections were developed in 
Physical Developer ABC solution (after Gallyas; containing Na carbonate citric acid, 
tungstosilicic acid and formaldehyde) with the development time being visually assessed. 
The development was stopped by briefly placing the sections in 0.5% acetic acid. The 
stained sections were then mounted on gelatinized glass slides and viewed under a Zeiss 
Axiovert 200M Marianas digital microscopy workstation equipped with the Slidebook 
imaging software. Images were stitched together to create a 10× montage using the Fiji 
Image Stitching Plugin as previously indicated [38].
Statistical Analysis
Statistically significant differences between groups were determined using one-way analysis 
of variance (ANOVA) followed by Student-Newman-Keuls pairwise multiple comparisons 
post hoc tests. Statistical significance is indicated as follows: * P<0.05, ** P<0.01.
Results
ApoE2 brain differentially expresses enzymes associated with cellular homeostasis, 
cellular bioenergetics, and synaptic transmission
In this study, we sought to determine the cortical proteome differences among the three 
human ApoE isoforms. Two-dimensional proteomic analysis was performed on 150 μg of 
cortical total protein derived from 6-month-old, female hApoE2-TR, hApoE3-TR, and 
hApoE4-TR mice. Comparisons between (a) ApoE2 and ApoE3 and (b) ApoE2 and ApoE4 
isoforms were evaluated using PDQuest software. From this analysis, 20 gel spots that were 
significantly differed in ApoE2 brain when compared to ApoE3 and/or ApoE4 were selected 
for identification via LC-MS/MS. Of the 20 spots analyzed, 8 proteins were identified with 
the filter parameters: (a) a percent coverage of greater than 9%, (b) a minimum number of 2 
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unique peptides, (c) a minimum peptide threshold of 95%, and (d) a minimum protein 
threshold of 95%. A complete listing of identified proteins with protein accession number, 
gene name, percent coverage, unique peptide number, and fold change relative to expression 
levels in ApoE2 brain with the corresponding p-value are indicated in Table 1. Of the 8 
proteins identified, 4 proteins exhibited significantly higher levels in ApoE2 brain versus 
ApoE3, including V-type H+-ATPase subunit 1B2 (Atp6v1b2, 1.67-fold change, p = 0.016), 
cytosolic non-specific dipeptidase (Cndp2, 1.12-fold change, p = 0.026), dimethylarginine 
dimethylaminohydrolase (Ddah1, 1.17-fold change, p = 0.021), and Glycine—tRNA ligase 
(Gars, 2.78-fold change, p = 0.044); while 1 protein, B-type creatine kinase (Ckb, 0.62-fold 
change, p = 0.033), was found to be higher in ApoE3 brain over ApoE2 brain. Likewise, a 
comparison between ApoE2 and ApoE4 brain yielded 4 proteins that were expressed at 
significantly higher levels in ApoE2 brain and 1 protein was found to be higher in ApoE4 
brain. Expression levels of cytochrome b-c1 complex subunit 1 (Uqcrc1, 1.35-fold change, p 
= 0.032), V-type H+-ATPase subunit 1B2 (Atp6v1b2, 2.05-fold change, p = 0.013), cytosolic 
non-specific dipeptidase (Cndp2, 1.38-fold change, p = 0.007), and glycerol-3-phosphate 
dehydrogenase 1-like (Gpd1l, 2.7-fold change, p = 0.020) were significantly higher in 
ApoE2 brain when compared with ApoE4 while the expression of mitochondrial aldehyde 
dehydrogenase 2 (Aldh2, 0.7-fold change, p = 0.025) was significantly reduced in ApoE2 
brain compared to ApoE4 brain.
ApoE2 brain exhibits higher expression of a key catalytic subunit of V-type H+-ATPase
To validate our initial findings from 2D-PAGE, immunoblot analysis was performed on 
cortical protein samples derived from the same hApoE2-TR, hApoE3-TR, and hApoE4-TR 
mice (n=5) and normalized to β-tubulin immunoreactivity. Of the 8 proteins identified 
(Table 1), we were particularly interested in Atp6v1B2 for three reasons: a) the expression 
levels of Atp6v1B2 were significantly higher in ApoE2 brain compared to both ApoE3 and 
ApoE4 brains, b) Atp6v plays an essential role in synaptic transmission by mediating the 
concentration of neurotransmitters into pre-synaptic vesicles, and c) of the 8 subunits that 
comprise the cytoplasmic domain of Atp6v, the B subunit is essential for ATP hydrolysis and 
thus successful proton transport [39, 40]. Consistent with findings from our proteomic 
analysis (Fig. 1B), the expression of Atp6v1B2 was reduced by 20% in ApoE3 brain (0.80-
fold change, p = 0.03) and 22% in ApoE4 brain (0.78-fold change, p = 0.04) when compared 
to ApoE2 brain (Fig. 1C). No significant change in Atp6v1B2 expression was observed 
between ApoE3 and ApoE4 brains (p = 0.671). These data confirm that ApoE2 brain 
exhibits a higher expression level of a key component of the catalytic domain of Atp6v when 
compared to both ApoE3 and ApoE4 brains.
Atp6v1B2 is altered by aging and AD pathology in female brain
To better understand the function of Atp6v1B2 in relation to brain aging and the 
development of AD pathology, we further examined the age-related changes in the protein 
expression of Atp6v1B2 in the cortices of 129/C57BL/6 (WT) and 3xTg-AD female mice at 
6, 9, 12 and 15 months of age. In WT mice, we observed a non-significant change in 
Atp6v1B2 expression at 9 months of age (0.86-fold change, p = 0.470) followed by a 
significant reduction at both 12 months (0.50-fold change, p = 0.039) and 15 months (0.43-
fold change, p = 0.032) of age when compared to 6-month-old animals. Though the 
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downward trend in Atp6v1B2 expression continued following 9 months of age, the change 
between 9–12 months of age (p = 0.061), 9–15 months of age (p = 0.070) and between 12–
15 months of age (p = 0.688) did not reach a level of significance (Fig 2A). In 3xTg-AD 
mice, similar to our observations in WT mice, we detected a non-significant change in 
Atp6v1B2 expression at 9 months of age (0.98-fold change, p = 0.42) when compared to 6-
month-old animals. However, unlike WT animals, we did not see a significant reduction in 
Atp6v1B2 expression until 15 months of age (0.41-fold change). The decline in Atp6v1B2 
expression at 15 months of age was significant when compared to both 6-month-old animals 
(p = 0.045) and 9-month-old animals (p = 0.042) and though the downward trend continued 
between 12–15 months of age, this change did not reach a level of significance (p = 0.226) 
(Fig. 2B). These data indicate that both aging and AD pathology alter the expression of 
Atp6v1B2 in female brain. To further examine the role of Atp6v1B2 in AD pathogenesis, we 
compared the expression of Atp6v1B2 in age-matched female WT and 3xTg-AD mice at 6, 
9, 12, and 15 months of age. We observed a significant decrease in Atp6v1B2 expression in 
3xTg-AD mice at both 6 months (0.67-fold change, p = 0.024) and 9 months (0.68-fold 
change, p = 0.021) of age when compared to age-matched WT females, indicating that 
Atp6v1B2 is reduced in the early development of AD pathology. Contrary to these data, we 
observed a profound increase in Atp6v1B2 expression in 3xTg-AD mice at 12 months of age 
when compared to WT controls, however this comparison did not reach a level of 
significance (1.42-fold change, p = 0.057). No significant change was detected between WT 
and 3xTg-AD mice at 15 months of age (1.16-fold change, p = 0.249) (Fig 2C). In order to 
investigate the possible association between the altered trajectory in Atp6v1B2 expression 
and the stage of AD pathology, 3xTg-AD mouse brain hemispheres were sectioned into 35 
μm coronal planes through the hippocampal region and subjected to Campbell-Switzer silver 
staining to detect Aβ plaques. Our data demonstrate that extraneuronal plaque formation is 
not visible until 3xTg-AD mice reach approximately 12 months of age indicating that the 
increase in Atp6v1B2 expression in 12-month-old AD animals is likely a compensatory 
response to the significantly advanced AD pathology (Fig. 2D).
Atp6v1B2 is localized to synaptic vesicles in primary hippocampal neurons
As Atp6v1B2 expression is significantly impacted by aging and the progression of AD 
pathology, and it is previously reported that Atp6v is critically involved in synaptic 
transmission, we next examined the distribution of Atp6v1B2 within neurons. In light of the 
fact that mouse and rat Atp6v1B2 share 100% sequence homology, we chose to utilize rat 
primary neurons as a model for this experiment. Hippocampal neurons were isolated from 
day 18 embryonic rat pups and stained with the axonal marker tau, the synaptic vesicle 
membrane marker, synaptophysin, and Atp6v1B2. Axons were imaged using three-
dimensional 60× oil immersion confocal microscopy with three-dimensional image stacks in 
0.10 μm planes. As expected, our analysis demonstrates a high level of overlap between 
synaptophysin and tau confirming the presence of synaptic vesicles within axons (Fig. 3A). 
Additionally, we detect a high degree of co-localization between Atp6v1B2 and tau 
indicating that Atp6v1B2 is also expressed within the axon (Fig. 3B). Moreover, our data 
indicate that synaptophysin and Atp6v1B2 co-localize within the axons of primary 
hippocampal neurons indicating the presence of Atp6v1B2 on the vesicular membrane (Fig. 
3C). Together, these imaging data confirm that Atp6v1B2 is predominantly localized on the 
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membrane of synaptic vesicles in the axons of neurons and are consistent with previous 
reports that implicate Atp6v1B2 in synaptic transmission (Fig. 3D).
Discussion
Human ApoE genetic isoforms (ApoE2, ApoE3, and ApoE4) play a differential role in the 
development of late-onset AD, with ApoE4 currently recognized as the most potent genetic 
risk factor. Existing literature has predominantly focused on the identification of ApoE4-
mediated AD-risk mechanisms via comparisons between ApoE3 and ApoE4 brains and 
between ApoE4 carriers and non-carriers with relatively few studies including the ApoE2 
genotype. To address this gap, our laboratory has initiated a series of studies aimed to define 
the molecular differences that could contribute to the differential impact of the three human 
ApoE isoforms in the development of AD; in particular, the molecular bases that separate 
ApoE2 brain from ApoE3 and ApoE4 brains. The goal of this study was to examine the 
cortical proteome differences in 6-month-old female hApoE2-TR, hApoE3-TR, and 
hApoE4-TR mice in an effort to determine the mechanisms by which ApoE2 delegates 
neuroprotection. Our data indicate that three ApoE brains differentially express enzymes 
primarily involved in cellular bioenergetics and synaptic transmission and provide a 
potential molecular rationale for the positive influences associated with the ApoE2 
genotype.
ApoE2 brain exhibits a more robust bioenergetic profile than ApoE3/ApoE4 brains
Energy hypometabolism occurs early in the preclinical development of AD and several 
reports have demonstrated that carriers of the ApoE4 allele exhibit deficiencies in key 
neuronal bioenergetic processes [41–44]. Using 6-month-old female hApoE-TR mice, our 
laboratory has recently provided the first evidence that the three human ApoE isoforms 
differentially regulate hippocampal signaling pathways involved in bioenergetics. Of 
importance, our data indicated significantly more robust Igf1-mediated signaling activity and 
downstream glucose uptake and metabolism in ApoE2 brain compared to ApoE3 and ApoE4 
brains [34]. In the current study, we have identified 4 enzymes involved in cellular 
bioenergetics that are significantly altered in ApoE2 brain when compared to ApoE3 and/or 
ApoE4 brains. Expression levels of mitochondrial cytochrome b-c1 complex subunit 1 
(Uqcrc1) and glycerol-3-phosphate dehydrogenase 1-like (Gpd1l) were both significantly 
increased in ApoE2 brain when compared to ApoE3 or ApoE4 brains. Uqcrc1 is one of the 
11 subunits that comprise the respiratory chain protein ubiquinol cytochrome c reductase, or 
Complex III, and is therefore crucial in the production of ATP. Gpd1l is a regulatory enzyme 
implicated in the modulation of cardiac sodium channels. While Gpd1l has not been 
previously implicated in the progression of any neurodegenerative disorders, it has been 
demonstrated that Uqcrc1 expression is significantly reduced in synaptosomal fractions of 
ApoE4 mice when compared to ApoE3 mice [45] - a finding that corresponds with our data. 
Contrary to these data, aldehyde dehydrogenase 2 (Aldh2) and B-type creatine kinase (Ckb) 
were both significantly down-regulated in ApoE2 brain when compared to ApoE3 or ApoE4 
brains. While the down-regulation of cellular bioenergetic enzymes in ApoE2 brain was not 
expected, a possible explanation could be found by examining the function of these enzymes 
within the cell. Aldh2, an enzyme found in the mitochondrial matrix, functions as a 
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protectant from oxidative stress [46] specifically through the detoxification of toxic 
aldehydes, like 4-hydroxynonenal [47], while Ckb primarily functions to create the 
secondary energy source phosphocreatine [48]. Therefore, it can be postulated that under 
normal resting conditions, an environment that a) contains less oxidative stress and b) is 
more glucose metabolically robust (i.e. ApoE2 brain) may not require the increased input of 
detoxifying enzymes and the increased generation of a secondary energy source thereby 
exhibiting reduced expression of enzymes such as Aldh2 and Ckb. Despite these findings, 
our data overall do further confirm the differential modulation of bioenergetic processes by 
human ApoE isoforms and bioenergetic robustness associated with ApoE2.
ApoE2 brain exhibits a more robust synaptic profile than ApoE3/ApoE4 brains
Cognitive impairment, a hallmark symptom of AD, could be the clinical consequence of a 
series of long-term molecular changes including a reduction in the expression of the synaptic 
proteome [49, 50] and a reduction in synaptic density [51], plasticity and transmission [52, 
53]. It is well established that the ApoE4 genotype is clinically associated with accelerated 
cognitive decline and earlier incidence of MCI. However, the neurophysiological phenotypes 
of the ApoE4 genotype are only recently being characterized on the molecular level. One 
study indicates that co-culture of ApoE4-expressing glial cells with wild-type neurons 
induces a loss of mature dendritic spines by negatively impacting the expression of 
glutamate receptors [54]. Dumanis et al. demonstrates significantly reduced cortical 
dendritic spine density in aged ApoE4-TR mice compared to age-matched ApoE2-TR and 
ApoE3-TR mice [55]. Young adult (7-month-old) ApoE4-TR mice display reduced 
excitatory synaptic transmission, dendritic arborization, and spine density in the absence of 
AD-related neuropathological hallmarks. This same study demonstrates significantly 
reduced synaptic transmission in 1-month-old ApoE4-TR mice when compared to age-
matched ApoE3-TR mice [52]. Additionally, the study demonstrates that the synaptic 
deficits associated with the ApoE4 genotype in young (1-month) mice were significantly 
attenuated in ApoE2/E4 heterozygous mice [52]. Collectively, these data indicate that the 
ApoE4 genotype negatively whereas ApoE2 positively impacts synaptic function.
In support of these findings, our proteomic analysis identified three proteins that were a) 
significantly increased in expression in ApoE2 brain compared to ApoE3 and/or ApoE4 
brain and b) are involved in some aspect of synaptic transmission. The first two proteins 
identified were found to be significantly upregulated in ApoE2 brain over ApoE3 brain. 
Dimethylarginine dimethylaminohydrolase (Ddah1) is a regulatory enzyme that mediates the 
N(G),N(G) asymmetric dimethyl-L-arginine (ADMA)-nitric oxide (NO) system and 
therefore regulates the levels of NO within the brain [56]. Glycine—tRNA ligase (Gars) is a 
ubiquitously expressed enzyme that catalyzes the synthesis of glycyl tRNA, a molecule that 
is required to insert glycine residues into proteins during translation [57]. Alternatively, Gars 
mutations have been implicated in the development of axonal neuropathies [58, 59] 
indicating the importance of Gars in the nervous system. While neither Ddah1 nor Gars 
expression have been previously implicated in AD pathogenesis, our data demonstrate 
significantly higher expression of both proteins in ApoE2 brain indicating that upregulation 
of Ddah1 and Gars may contribute to the positive impact on synaptic function associated 
with the ApoE2 genotype.
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The third synaptic protein identified, and the primary focus of our follow-up studies, is a key 
component of the V-ATPase (Atp6v): an intricate proton pump that has the highest 
expression in the brain and accounts for approximately 20% of the total protein resided on 
the membrane of presynaptic vesicles [60]. Atp6v is composed of a total of 13 subunits 
separated into two functionally distinct complexes (Fig. 3D–F). The 5-subunit membrane-
embedded V0 complex facilitates the movement of protons across a membrane driven by 
energy generated via ATP hydrolysis by the 8-subunit cytoplasmic V1 complex [40]. Of the 
8 subunits that comprise the V1 complex, subunits A (Atp6v1A) and B (Atp6v1B), which 
are arranged in a heterohexameric rotor pattern composed of 3 alternating A and B subunits, 
bind ATP via catalytic residues located in Atp6v1A [61] and with the structural support of 
Atp6v1B perpetuate the hydrolysis of ATP to ADP at the interface between Atp6v1A and 
Atp6v1B subunits [62, 63]; thus this heterohexameric complex is considered to be the 
catalytic core of Atp6v [40, 64, 65]. On the membrane of synaptic vesicles, Atp6v works in 
coordination with neurotransmitter transporters, such as acetylcholine, glutamate and GABA 
transporters, to facilitate neurotransmitter concentration into synaptic vesicles (Fig. 3D) [66, 
67]. Inhibition of Atp6v activity via bafilomycin A1 treatment has been shown to a) 
significantly deplete glutamate and GABA accumulation in synaptic vesicles, b) 
substantially reduce glutamatergic and GABAergic synaptic transmission, and c) reduce the 
frequency and amplitude of miniature postsynaptic currents in rat primary hippocampal 
neurons [68], connecting Atp6v dysfunction to impaired synaptic transmission. Our data 
indicate that ApoE brains of three isoforms differentially express Atp6v1B2, with ApoE2 
brain exhibiting the highest expression and ApoE4 exhibiting the lowest. As Atp6v1B serves 
as one of the two essential building blocks that comprise the catalytic core of Atp6v, 
significantly increased Atp6v1B2 expression in ApoE2 brain over both ApoE3 and ApoE4 
brains suggests that the ε2 allele of the ApoE gene may confer a positive impact on the 
function of Atp6v in the brain. This promising implication, however, needs to be extensively 
investigated in future studies.
Pertaining to Atp6v1B2 expression in AD, the current literature contains 3 separate 
proteomic studies that demonstrate significantly increased expression of Atp6v1B2 in 14–
16-month-old triple transgenic mice and in 9-month-old APP/PS-1 transgenic mice [69–71]. 
Contrary to these data, a more recent gene array study performed in normally aging F344 
rats demonstrates significantly reduced expression of Atp6v1B2 in 12–23-month-old rats 
[72]. Taken together, these data indicate that Atp6v1B2 expression is reduced with normal 
aging but increased in aged AD animals. To further clarify the impact of aging and AD 
progression on the expression of Atp6v1B2, we examined Atp6v1B2 protein levels in 
female WT and 3xTg-AD mice at 6, 9, 12, and 15 months of age. Consistent with the 
previously discussed study by Kadish et al., our data indicate that Atp6v1B2 expression is 
significantly reduced with aging in WT mice beginning at 12 months of age. These data 
correspond with the well-established aging-mediated decline in synaptic transmission [31, 
36, 72] and suggest that reduced Atp6v1B2 expression could be an underlying contributor to 
age-associated cognitive decline. As well as being impacted by age, we also find that 
Atp6v1B2 expression is significantly reduced in response to the progression of AD 
pathology with the most severe decline occurring at 15 months of age in 3xTg-AD mice. A 
further comparison between age-matched female WT and 3xTg-AD mice indicates a 
Woody et al. Page 12













significant reduction in Atp6v1B2 expression in AD mice compared to WT mice at 6 and 9 
months of age and a nearly significant increase in Atp6v1B2 expression at 12 months of age 
with no significant change at 15 months of age. These data suggest that Atp6v1B2 
deficiency could contribute to the gradual loss of synaptic integrity during early disease 
progression while the increase observed in 12-month-old animals could be a compensatory 
response to the significantly advanced AD pathology including the onset of Aβ plaque 
formation and cognitive deficit associated with the animal model at this age.
In addition to being regulated by ApoE status, aging, and the progression of AD pathology, 
emerging evidence suggests that Atp6v function is integrally linked to cellular bioenergetics, 
specifically glycolysis. It has been previously reported that the glycolytic enzyme 
phosphofructokinase-1 interacts with the a-subunit of the V0 complex (Atp6v0a) [73]. 
Additionally, several reports have indicated that aldolase, another glycolytic enzyme, 
interacts with multiple Atp6v subunits including Atp6v1B, Atp6v1E, and Atp6v0a [74]. 
These studies also demonstrated that treatment with extracellular glucose significantly 
increased the interaction between aldolase and Atp6v subunits and that disruption of the 
aldolase-Atp6v1B interaction results in the disassembly of Atp6v [74, 75]. Furthermore, 
Nakamura and colleagues demonstrated that Atp6v function is completely inhibited upon 
treatment with the glycolytic inhibitor, 2-deoxy-D-glucose. This same study indicated that 
treatment with the mitochondrial electron transport chain inhibitor, antimycin, only partially 
reduced Atp6v function while the PI3K inhibitor, wortmannin, completely abolished 
glucose-mediated activation of Atpv6 activity [76]. In addition to these data, Sautin and 
colleagues demonstrated that stimulation with extracellular glucose initiates the rapid 
assembly of the V1 and V0 domains while glucose deprivation induces the reversible 
disassembly of the two protein complexes [77]. Taken together, these studies indicate that 
the glycolytic pathway directly regulates the assembly, disassembly, and function of Atp6v. 
As we have previously demonstrated that ApoE2 brain exhibits a more bioenergetically 
robust profile, and the glycolytic pathway appears to directly impact Atp6v function, we 
hypothesize that the enhanced synaptic function observed in ApoE2 brain is, in part, due to 
an ApoE2-mediated upregulation of Atp6v subunit expression. Moreover, we hypothesize 
that the increased glucose uptake and metabolism previously observed in ApoE2 brain 
provides a direct source of ATP and protons for Atp6v and thus facilitates increased Atp6v 
activity thereby increasing neurotransmitter concentration and ultimately synaptic function 
(Fig. 4).
Conclusions
In this study, we examined the cortical proteome differences among the three human ApoE 
isoforms, with the primary focus on the differences presented in ApoE2 brain compared to 
ApoE3 and ApoE4 brains. The data indicate that the three ApoE brains are significantly 
different in two major areas – bioenergetically and synaptically – with ApoE2 brain 
exhibiting a much more robust profile in both areas. Of particular significance, our data 
demonstrate for the first time that ApoE isoforms differentially modulate a key component 
of the catalytic domain of Atp6v, a complex that is crucial for synaptic transmission, with 
ApoE2 brain exhibiting the highest expression and ApoE4 brain exhibiting the lowest. An 
extension of these studies indicates that the expression of Atp6v1B2 is significantly reduced 
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before the onset of plaque formation in 3xTg-AD mice compared to WT animals suggesting 
that Atp6v1B2 deficiency could contribute to the gradual loss of synaptic integrity during 
early disease progression. These findings warrant further in-depth investigations to explore 
the potential role of Atp6v as an underlying mechanism responsible for the clinically proven 
neuroprotective and cognition-favoring properties associated with the ApoE2 genotype.
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Figure 1. ApoE2 brain expresses significantly higher levels of Atp6v1B2
(A) A representative 2D gel image of protein spots derived from 6-month-old female 
hApoE2-TR mouse cortex. Selected proteins are circled on the gel image and protein 
identification number corresponding to Table 1 is indicated adjacent to protein spot. (B) 
Proteomic analysis of 150 μg of cortical protein demonstrates that the expression of 
Atp6v1B2 is significantly higher in ApoE2 brain when compared to both ApoE3 and ApoE4 
brains. The data are shown as a vertical point plot with the mean value indicated by a 
horizontal line; n=3. (C) Immunoblot analysis of cortical tissues harvested from 6-month-
old female hApoE2-TR, hApoE3-TR, and hApoE4-TR mice confirmed the proteomic 
results. The data are shown as a box plot with the bottom bar representing the lowest data 
point, the middle bar representing the median, and the upper bar representing the highest 
data point; n=5. *p<0.05 when compared to ApoE2 brain.
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Figure 2. Aging and AD pathology alter the expression of Atp6v1B2 in female brain
Immunoblot analysis was performed on cortical protein samples derived from female (A) 
129/C57BL/6 and (B) 3xTg-AD mice at ages of 6, 9, 12, and 15 months. n=4–5; *p<0.05. 
(C) Immunoblot analysis of Atp6v1B2 expression in cortical protein samples derived from 
age-matched female 129/C57BL/6 and 3xTg-AD mice. n=4–5; *p<0.05. (D) Campbell-
Switzer staining of mouse brain hemispherical sections harvested from 9- and 12-month-old 
3xTg-AD mice. Campbell-Switzer staining detects the presence of Aβ plaques shown in 
black.
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Figure 3. Atp6v1B2 is localized to the vesicular membrane of synaptic vesicles
(A–C) Primary hippocampal neurons were fixed on day 15 and stained for tau (green), 
synaptophysin (blue) and Atp6v1B2 (red) immunoreactivity. Images were visualized using 
60× oil immersion confocal microscopy and acquired in three-dimensional stacks with 0.10 
μm planes. (D–F) A schematic representation of Atp6v on the membrane of synaptic 
vesicles in presynaptic (axonal) nerve terminals. The 8-subunit V1 complex generates energy 
via ATP hydrolysis which allows the 5-subunit V0 complex to transport protons across the 
vesicular membrane. Simultaneously, the neurotransmitter transporters utilize this 
electrochemical gradient to concentrate neurotransmitters into the synaptic vesicles.
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Figure 4. A representative schematic of our proposed hypothesis
In order for synaptic transmission to occur, neurotransmitters must first be synthesized, 
concentrated in synaptic vesicles, and released across the synaptic cleft. V-ATPase (Atp6v), 
a multi-subunit proton pump, is the primary mediator of ATP-dependent concentration of 
neurotransmitters into synaptic vesicles and is thus vital for healthy synaptic transmission. 
Our data indicate that human ApoE isoforms differentially modulate the expression of 
Atp6v1B2, a key component of the catalytic core of Atp6v, with ApoE2 brain exhibiting the 
highest expression and ApoE4 brain exhibiting the lowest. Moreover, several studies have 
indicated that the glycolytic pathway of glucose metabolism is a direct regulator of Atp6v 
function. Based on these findings, we hypothesize that ApoE2 upregulates Atp6v in the 
brain and that the increased glucose uptake and metabolism previously observed in ApoE2 
brain provides a direct source of ATP and protons for Atp6v thus facilitating increased 
Atp6v activity. Moreover, we hypothesize that the increased activity of Atp6v results in 
significantly increased neurotransmitter concentration and thus enhanced synaptic function.
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